CIRSE 2023 – HDT SESSIONS
VENOUS STENTING + IVUS

Boston Scientific

WALLSTENT™ UNI VENOUS STENT

Clinically proven; Case after case

High durability
Specifically engineered to provide **fracture resistance**.

Braided architecture
Braided design with Elgiloy® material provides **compression resistance** in venous anatomy.

Unique conformability
Designed for optimal **conformability** so it can be deployed effectively in curved / tapered vessels.

Avvigo system & OptiCross catheter – BSC IVUS system

Leveraging confidence



State-of-the-Art Multi-Modality Platform

Best-in-Class IVUS Imaging Catheters

- **COOK TriForce® Peripheral Crossing Set**
  - 5.0 Fr Flexor sheath, with a 4.0 Fr CXI Support Catheter
  - Accepts a 0.035-inch diameter wire guide
  - 7.0 Fr introducer is required for TriForce®
  - Available with straight/curved sheaths and straight/curved Tip
- **COOK Zilver Vena® Venous Self-Expanding Stent**
  - 7Fr introducer system
  - Stent diameter 14 & 16 mm
  - Stent length 60, 100, 140 mm
  - Delivery system length 80 & 120 cm



optimed venous stents









	sinus-Obliquus	sinus-Venous	sinus-XL	sinus-XL Flex
Application device size:	10 F / 100 cm	10 F / 100 cm	10 F / 100 cm	10 F / 100 cm
Stent Ø:	14 – 18 mm	10 – 18 mm	16 – 36 mm	14 – 24 mm
Stent length:	80 – 150 mm	60 – 150 mm	30 – 100 mm	40 – 160 mm
Indication:	MTS	DVT / PTS	VCCS	VCCS / DVT / PTS
Area of application:	Iliofemoral	Iliofemoral	Vena cava	Vena cava / Iliofemoral

Philips Intravascular Ultrasound

See clearly. Treat optimally.



Plug and Play

IntraSight

Mobile & integrated systems

Venous Self-Expanding Stent System

Abre™

The Abre™ Venous Self-Expanding Stent system is designed for the unique challenges of venous disease. It offers easy deployment, to let physicians focus on their patient, and delivers demonstrated endurance, to give patients freedom of movement.[1,2]

The ABRE clinical study demonstrates the safety and effectiveness of the Abre™ Venous Stent.[1]

- 88% primary patency at 12 months*
- 98% freedom from MAEs at 30 days†
- 0% fracture rate at 50 years in bench testing[2]
- 0% fracture rate in clinical trial with 44% of stents extending below inguinal ligament into the CFV[1]

1. ABRE CSR v1.2 30/JUL/2020.
2. Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.

* Primary Patency was defined as meeting all of the following criteria at 12 months post-procedure: Freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization.

† MAEs included all-cause death, clinically significant pulmonary embolism, procedural major bleeding complication, stent thrombosis, and stent migration. MAEs were adjudicated by a Clinical Events Committee, except stent thrombosis and stent migration, which were assessed by an imaging core laboratory.

Medtronic